Executive Search and Leadership Development firm Borderless recently sponsored the Fourth Annual BioNJ CEO Summit, which brought together some of the most influential leaders in the life sciences industry to share their knowledge, experiences and views on today’s evolving market access and commercialization environment. Speakers explored issues and considerations that need to be addressed along the development continuum, including raising capital, pricing, post-launch and politics.
“A clear message was that biopharmaceutical companies must develop a strategy early for Market Access and begin implementation in the pre-clinical phase of drug development. A sharp focus on pricing and transparency – currently under public scrutiny in the US – reinforces our observation that the increased demand and competition for skilled Market Access professionals will not abate,” explains Borderless Consultant Andrei Costache.
BioNJ, The Gateway to Health, is a network of more than 400 Members, including Borderless, representing research-based life sciences companies and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount.
After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.
Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.
UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.
